Searchable abstracts of presentations at key conferences in endocrinology

ea0070oc3.6 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

11β-Hydroxysteroid dehydrogenase type 1 inhibition protects against the development of adverse metabolic and bone effects of prednisolone: A randomized, double-blind, placebo-controlled trial

Othonos Nantia , Pofi Riccardo , Arvaniti Anastasia , Whittaker Andrew , Stewart Paul , Coleman Ruth , Agbaje Olorunsola , Milton Joanne , Holman Rury , Tomlinson Jeremy W

Glucocorticoids (GC) are commonly prescribed, but their use is associated with significant adverse metabolic and bone effects. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active GC within tissues, tightly controlling the availability of GC to bind and activate the GC receptor; Our preclinical data have shown that 11β-HSD1 knock out mice resist the adverse effects of exogenous GC excess. We have now conducted a randomized, double-blind, placebo...